Insider · CIK 0001977689
Andrew Stewart Plump
Files at TAK (TAKEDA PHARMACEUTICAL CO LTD). First filing Aug 12, 2026, latest Sep 3, 2026.
In brief
Andrew Stewart Plump files SEC Form 4 as president and director at TAK (TAKEDA PHARMACEUTICAL CO LTD). Since Aug 12, 2026, Andrew Stewart Plump has reported 0 open-market buys worth $0 and 3 open-market sells worth $5.3M, the latest filed on Sep 3, 2026.
A track record needs three past buys with six months of prices behind them; Andrew Stewart Plump has 0, so none is measured yet.
The newest scored trade: sold $2.1M of TAK on Sep 2, 2026, filed Sep 3, 2026, scored 43 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 3 sells worth $5.3M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TAK: TAKEDA PHARMACEUTICAL CO LTD
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | TAKEDA PHARMACEUTICAL CO LTD | $2.1M 116,191 shares | -44% | +39% from low-2% from high | |
| 30Weak | TAKEDA PHARMACEUTICAL CO LTD | $363k 19,651 shares | -7% | +39% from low-2% from high | |
| 65Notable | TAKEDA PHARMACEUTICAL CO LTD | $2.8M 165,393 shares | -18% | +33% from low-7% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 2, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | 116,191 0.01% of outstanding | $2.1M | Sep 2, 2026 | $363k |
| Aug 19, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | 19,651 0.00% of outstanding | $363k | Aug 19, 2026 | none |
| Jul 13, 2026 | TAK Takeda Pharmaceutical Company Limited | 179,239 0.13% of outstanding | $3.0M | Jul 13, 2026 | none |
| Jul 9, 2025 | TAK Takeda Pharmaceutical Company Limited | 169,313 0.14% of outstanding | $2.6M | Jul 9, 2025 | none |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | SOpen-market sale American Depositary Sharesindirect: By Trust10b5-1 | -116,191 | $18.49 | $2.1M | 145,465 | 40 d ago |
| Aug 19, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | SOpen-market sale American Depositary Sharesindirect: By Trust10b5-1 | -19,651 | $18.49 | $363k | 261,656 | Aug 21, 2026 |
| Aug 10, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | SOpen-market sale American Depositary Shares | -165,393 | $17.10 | $2.8M | 766,569 | Aug 12, 2026 |
| Jul 1, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | AGrant or award American Depositary Shares | +125,390 | $0.00 | $0 | 931,962 | Jul 6, 2026 |
| Apr 27, 2026 | TAK TAKEDA PHARMACEUTICAL CO LTD | AGrant or award American Depositary Shares | +212,470 | $0.00 | $0 | 806,572 | Apr 28, 2026 |
Questions about Andrew Stewart Plump
Answered from the filings on this page, as of the latest one.
Is Andrew Stewart Plump buying or selling?
In the last 12 months Andrew Stewart Plump reported 0 open-market buys worth $0 and 3 open-market sells worth $5.3M on SEC Form 4; the latest was sold $2.1M of TAK on Sep 2, 2026. Grants, option exercises and tax withholding are not counted.
How did Andrew Stewart Plump's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Andrew Stewart Plump has 0.
Where does Andrew Stewart Plump file Form 4?
Andrew Stewart Plump has filed Form 4 at TAK (TAKEDA PHARMACEUTICAL CO LTD) as President, R&D. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.